T0	Participants 105 130	resectable rectal cancer:
T1	Participants 301 314	rectal cancer
T2	Participants 321 487	radiotherapy institutions participating in the framework of a multicentre phase-III European Organization for Research and Treatment of Cancer (EORTC) clinical trial.
T3	Participants 488 587	Twelve radiotherapy departments with more than 10% of the evaluable patients recruited in the trial
T4	Participants 649 675	Participating institutions
T5	Participants 695 911	five full patient records with the chemotherapy charts, surgical and pathology reports, radiation treatment charts, treatment planning calculations, computed tomography (CT) scans, portal images and follow-up charts.
T6	Participants 930 960	5 patients per institution was